WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Rheumatoid Arthritis v A1, newly added concepts are denoted by green color outlines, Therapeutic Efficacy Point is the intersection of Observation or Assessment, Concepts are denoted by solid round-edged rectangle, Time Points instantiated_by - date - visit # - Week #, FDA EFFICACY CRITERIA FOR RHEUMATOID ARTHRITIS include Clinical response, CM Details documented_at baseline, Clinical response has_outcomes Disease Activity Score (DAS28), FDA EFFICACY CRITERIA FOR RHEUMATOID ARTHRITIS include major covariates Rheumatoid Factor, FDA EFFICACY CRITERIA FOR RHEUMATOID ARTHRITIS include Radiographic Response, Physical Function measured_at Time Points, FDA EFFICACY CRITERIA FOR RHEUMATOID ARTHRITIS include major covariates Geographic Region, Time Points instantiated_by - date - visit # - Week #, Oral Disease-modifying antirheumatic drug instantiated_by Yes/No, Swollen joint count instantiated_by - Present - Absent - Not Done - N/A, MTX instantiated_by Yes/No, Health Related Quality Of Life (HRQOL) has outcome assessment Short Form (SF-36), Oral corticosteroids instantiated_by Yes/No, Physical Function has outcome assessment Health Assessment Questionnaire - Disability Index (HAQ-DI), FDA EFFICACY CRITERIA FOR RHEUMATOID ARTHRITIS include major covariates Anti-cyclic Citrullinated Peptide, American College of Rheumatology score (ACRx) has outcome assessment Health Assessment Questionnaire - Disability Index (HAQ-DI)